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ABSTRACT 
The article discusses the relationship between oxidative stress (OS) and pathological conditions, the possibilities and benefits of 
estimating OS considering the integral antioxidant activity (AOA) as an OS criterion, and using a simple accessible hybrid 
potentiometric method (HPM) with a mediator system for AOA monitoring. The results of AOA of blood serum in healthy volunteers 
and patients with various diseases are presented. Preliminary reference values are found. The lower levels of AOA of blood serum in 
patients with different diseases in comparison with the control group are observed. The potential mechanisms of changes in the AOA 
levels and it’s clinical significance are discussed from the position of biointerfaces interplay. With AOA equal or greater than 1.40 
mmol-eq l–1 the person is healthy, the range from 0.95 to 1.40 mmol-eq l–1 indicates that the patient is at risk and needs to undergo a 
further medical examination. When AOA blood serum is below 0.95 mmol-eq l–1, detailed diagnostics and relevant treatment are 
required. The findings allow suggesting that the approach determine antioxidant/oxidant activity of biological fluids holds considerable 
promise for monitoring OS; it opens up new opportunities in expanding the use of analytical chemistry in medicine. 
Keywords: Oxidative stress; Antioxidant activity; Antioxidants; Hybrid potentiometric method; Cardiovascular diseases; Cancer. 
 
1. INTRODUCTION 
 The relationship between oxidative stress (OS) and the 
state of human health has become more clear for the latest decades 
as the result of research in this field carried out in chemical, 
biological and medical laboratories of the world [1–3]. The term 
"oxidative stress" refers to the imbalance between the production 
of oxidants (hydrogen peroxide, organic hydroperoxides, nitric 
oxide, oxygen and nitrogen reactive species, etc.), which generate 
oxidation processes, and exhaust activity of the system of 
antioxidant protection of the living organism. The latter suppresses 
the generation of oxidants or scavenges them [4–6]. 
 It is well known that the energy required for the life of 
aerobic organisms is formed in cells in the oxidation of certain 
substrates, primarily during oxidative phosphorylation [7]. In the 
mitochondria, the oxidation of glucose with oxygen to carbon 
dioxide and water, localized at the respiratory chain at the cristes 
of mitochondria results in the synthesis of adenosine triphosphate 
acid, with more than 90 % of the oxygen consumed reduced to 
water with the participation of the enzyme cytochrome oxidase 
[8]. A very small part of the oxygen is converted into partially 
reduced products – reactive oxygen species (ROS): superoxide 
(O2
•–), hydrogen peroxide (H2O2), hydroxyl radical (OH
•); unlike 
oxygen, they are reactive, whereby in normal conditions and at 
physiological concentrations participate in the processes of 
growth, differentiation, development and cell death, as well as in 
several other processes of bioregulation as natural molecules, 
signaling, intracellular messengers and potential factors of 
intercellular communication [9]. Normally, excess of ROS is 
scavenged by antioxidant defense system in the mitochondria. In 
case of excessive formation of ROS, as well as their insufficient 
inactivation by the system of antioxidant protection of the body, 
there is a phenomenon of OS, which causes the development of 
oxidative destruction of deoxyribonucleic acid (DNA), proteins, 
lipids, carbohydrates, and damage of biomembranes, cells, tissues 
[10], i.e. expansion of aggressive chain chemical reactions of 
biooxidation out of the borders of the cell organells and 
membranes. The modern definition of OS was proposed in 1991 
by H. Sies, who considered OS as "imbalance between pro-
oxidants and antioxidants in favor of oxidizing substances, leading 
to possible damage" [11]. In recent years, special attention is paid 
to the need to include in the concept of OS violations of signal 
functions of ROS: OS is proposed to be considered as "an 
imbalance between oxidants and antioxidants in favor of oxidants, 
leading to a violation of redox signaling and control and/or 
molecular damage" [6, 12].  
 OS forms the basis for] developing of main pathological 
processes within a wide range of diseases (including 
cardiovascular, endocrine, respiratory, neurodegenerative diseases, 
cancer; infertility; anxiety and depressive disorders, etc.) [1, 2]. 
Involvement of OS mechanisms in pathogenesis of multiple 
diseases can be explained by universality and importance of redox 
reactions occurring in human cells both in normal and pathological 
conditions. The universality of OS makes its measure and 
monitoring as a possible integral indicator of health status an 
important task. One of the main problems associated with the 
study of OS is the existence of a large number of different 
methods for its assessing and the lack of a common standard for 
such measurements [13]. There are many approaches and attempts 
to measure the OS level and activity of oxidants by the assessment 
of the properties of separate oxidants and the products of oxidation 
reactions - the received data are often characterized by ambiguity 
and inconsistency, it makes published results incomparable and 
irrelevant for diagnostic purposes [13–15]. The degree of 
expression of chain/oxidation reactions, initiated by free radicals, 
due to their non-specificity and significant differences in the 
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response of antioxidant systems, cannot and should not be 
considered as an independent diagnostic feature, and as the only 
cause of OS [16]. The significant problem is the understanding of 
the location of OS reactions in the cells and cell membranes and 
their surfaces in concrete cases and diseases, the evaluation of 
mechanisms, limiting or increasing their development. The 
processes of oxygen and products of its metabolism diffusion 
through several biointerfaces (alveolar-blood, blood-organ 
histohaematic barriers, biomembranes (cells and mitochondria) are 
difficult to be measured. Many existing ways of OS detection use 
chemical methods to determine individual substances that are 
products of oxidation by free radicals, thus fixing the 
consequences caused by OS. There are many serious limitations 
for accurate measurement of oxidants level – after sampling the 
rapid changes in composition of complex biological matrices are 
usually obtained, there are multiple compounds with different 
chemical nature, and different antioxidant and oxidant properties, 
with difficult interaction in biological matrix, some of them can 
achieve synergy effect, many of them (reactive oxygen and 
nitrogen species) have short lifetime, etc. 
 The development of radical oxidative processes in a living 
organism is limited by the action of antioxidant system aimed at 
retaining pro- and antioxidant balance. Thus, the study of 
antioxidant defense system seems to be the appropriate way for 
monitoring and evaluation of OS. A lot of works concerning the 
properties of separate antioxidants and their groups were 
published, but the determination of total content of antioxidants 
can be preferable because it is impossible to determine all 
different compounds exhibiting antioxidant properties, and 
possible synergism of the action of antioxidants and many other 
known and unknown factors modulating their antioxidant 
properties in vivo in each specific situation cannot be taken into 
account [17, 18]. The huge problem is that the term "antioxidant 
properties" has a different understanding of scientific publications; 
some of them do not have specific interpretations or use relative 
units to measure it, making the obtained results difficult or 
impossible to compare [19, 20].  
 One of the integral correct diagnostic indicators of the 
balance in the system of antioxidants/pro-oxidants as a whole is 
the antioxidant activity (AOA), by which we understand the total 
concentration of antioxidants in the biological sample [21]. AOA 
of the biological system is determined by a set of protein, enzyme 
and non-enzyme antioxidants, quantitatively determining the 
integral value of AOA [22]. 
 Since the AOA reflects the properties of the system as a 
whole and is determined by a complex of compounds, it is 
advisable to use methods for determining AOA as an integral 
parameter. 
 A number of methods of AOA determination are described 
[3, 5, 14, 15, 22–26]. 
  Some authors use stable radicals synthesized preliminary 
or during the analysis. Since the composition of used and natural 
radicals is different, it should be recognized that their interaction 
with antioxidants should also be different. The latter makes the 
interpretation of the results of the analysis not always correct.
 With rare exceptions, different relative values are usually 
used as the parameter characterizing the OS, which makes the 
results and conclusions of such investigations incomparable. From 
our point of view, electrochemical methods [27, 28] are preferable 
because the methods are simple, as a rule, give the result in units 
of concentration. However, in this case, the latter quality is not 
always realized. 
 The hybrid potentiometric method (HPM), which is free 
from these drawbacks, was described in several earlier works [29, 
30]. It was shown, those mentioned fundamental difficulty could 
be overcome by inserting the sample in a mediator system, 
containing the oxidized and reduced forms of the element and 
chemically react with antioxidants or oxidants. At the same time, a 
reversible signal is formed in this case due to the reaction of the 
mediator system components with the analyte. Thus, the use of the 
mediator system allows for measuring the equilibrium potential 
rather than the unstable stationary one. 
 Based on these considerations, we think, that HPM appears 
to be preferable for AOA determination, estimation of OS and use 
it in clinical investigations. 
 The important goal is to estimate the normal values of 
AOA in healthy people, deviations of AOA in patients with 
different diseases, and explain the possible cause of such 
deviations.  
 The aim of this work is to determine the boundaries of 
normal levels of AOA in healthy people, to compare these values 
with the AOA levels obtained in patients with arterial 
hypertension and cancer, and to assess the possibility of use of 
AOA values measured by a HPM in practice. 
2. MATERIALS AND METHODS 
2.1. Ethic statements. 
 The study was conducted in accordance with the rules of 
Good Clinical Practice and Declaration of Helsinki. All patients 
who were involved in the study have provided informed consent. 
The protocol of the study was approved by the Ethics Committee 
of “Medical Technologies” JSC (Project identification code 16-01-
18 MT-AO). 
2.2. Study groups. 
 305 people aged from 19 to 89 years were involved in the 
study. Three groups were formed: the group of 110 healthy 
volunteers; the group of 170 patients with cardiovascular diseases 
(CVD): arterial hypertension (HT) of stages I-III (in 34 patients 
the HT of III stage was complicated with stable coronary heart 
disease (CAD)) in accordance with the European Society of 
Cardiology and European Society of Hypertension of Cardiology 
Guidelines for the management of arterial hypertension, 2018; the 
group of 25 patients with diagnosed cancer (adenocarcinomas of 
different locations, verified by biopsy and histochemical test), 10 
of them with generalized forms of cancer (metastases), 15 – with 
non-generalized forms. Patients of control group have no chronic 
diseases, their anthropometric data, results of objective 
examination, biochemical and clinical full blood-count tests, urine 
test, electrocardiogram data and spirometry test were within 
normal values. In patients with arterial hypertension, the values of 
the following parameters were additionally studied: total 
cholesterol, high and low density lipoproteins, uric acid, creatinine 
concentrations in serum; measurement of the pulse wave velocity, 
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measurement of the thickness of the intima-media complex of the 
common carotid arteries were also performed. 
The exclusion criteria were the presence of chronic renal and 
hepatic failure, respiratory failure, severe heart failure, blood 
diseases, cerebral ischemic stroke or myocardial infarction within 
6 months before the date of inclusion in the study, acute infectious 
diseases. 
2.3. Blood collection and sample preparation. 
 Blood sampling of patients with cancer and arterial 
hypertension was performed at fasting in the early morning hours 
(7.00–8.30), in healthy volunteers – at fasting in the early morning 
(7.00–8.30) and morning (8.31–10.00) hours. Blood was taken by 
venipuncture at the bend of the elbow joint into polyethylene 
terephthalate vacuum tubes (Chengdu Puth Medical Plastics 
Packaging Co., Ltd., China) containing a coagulation activator 
(SiO2). To obtain serum, the blood was centrifuged at a speed of 
3500 rpm for 15 minutes using centrifuge SM–6M (SIA ELMI, 
Latvia).  
2.4. Blood clinical analysis. 
 A full blood count blood test was performed at BC-6800 
hematology analyzer (Shenzhen Mindray Bio-Medical Electronics 
Co., Ltd., China) and biochemical tests were performed at BA-400 
biochemical analyzer (Biosystems S.A., Spain). 
2.5. Determination of Blood Serum АОА. 
 HPM was used for analysis. Serum sample was introduced 
into the solution, containing 0.01 М K3[Fe(CN)6], 0.0001 М 
K4[Fe(CN)6], 0.0545 М Na2HPO4 and 0.0121 М KH2PO4 (pH 
7.4). Potential shift (signal) observed as a result of signal 
generating reaction (1) between antioxidants containing in the 
sample and K3[Fe(CN)6]: 
           
 –                   
 –         , (1) 
where a and b are the stoichiometric coefficients, AO is the 
antioxidant(s), AOOx is the oxidized form of the antioxidant(s). 
Measurements were carried out at the temperature 23 ± 3 °С using 
the potentiometric analyzer Antioxidant (Antioxidant Ltd., 
Russia). AOA was calculated with the use of equations (2) and 
(3): 
                                   
    –      
   
                                     (2) 
                                
    
    
                                          (3) 
where E is the initial potential of the mediator system, V; E1 is the 
potential of the mediator system, established after the introduction 
of the sample, V; СOx – concentration of K3[Fe(CN)6], M; CRed is 
the concentration of K4[Fe(CN)6], M; n is the number of electrons 
in the electrode reaction (here n = 1); F is the Faraday constant 
(96485.34 C/mol); R is the universal gas constant (8.314 J/( 
mol×K)); T is the absolute temperature, K; d is dilution of the 
sample in the electrochemical cell (for plasma and serum d ≤ 6). 
Analysis of blood serum by HPM was performed using two-
electrode cell comprising a platinum screen-printed electrode (Iva 
Ltd., Russia), which served as an indicator electrode and 
silver/silver chloride electrode Ag/AgCl, 3.5 M KCl type EVL-
1M3.1 (JSC Gomel Plant of Measuring Devices, Belorussia) as a 
reference electrode. After operation in a biological matrix (blood 
serum), the platinum screen-printed electrode was regenerated by 
annealing at 750 °C for 1 hour [31]. 
2.5. Pulse wave velocity measurement. 
 Determination of the pulse wave velocity was carried out in 
patients with arterial hypertension in accordance with the 
commonly used classical method by means of simultaneous 
registration of sphygmograms of carotid, radial and femoral 
arteries on the device POLY-SPEKTR-8/E with the help of 
software Poly-Spectr.NET with the connected module Poly-
Spectr-SRPV (Neurosoft Ltd., Russia). At the distance from the 
bifurcation of common carotid artery to the proximal part of 
femoral artery the pulse wave of elastic type (Se) vessels was 
measured and determined, and at the distance from the bifurcation 
of common carotid artery to the proximal part of radial artery the 
pulse wave velocity of muscular type (Sm) vessels was 
determined. 
2.6. Intima-media thickness measurement. 
 Ultrasound examination of common carotid arteries intima-
media complex was performed on at the ultrasound scanner 
Philips IU–22 (Philips N.V., Netherlands) by the linear probe with 
the working frequency of 5-12 MHz. The measurements were 
carried out with the accordance to a commonly used method, by 
the experienced physician, manually at three points of each 
common carotid artery posterior wall, in the zone located 1 cm 
proximal to the bifurcation of the common carotid artery. The 
intima-media thickness (IMT) was measured as the distance 
between the vessel lumen – intimal layer surface boundary and the 
media –adventitia layers boundary. The arithmetical mean of three 
dimensions was calculated, its value was taken as the value of 
IMT.  
 2.7. Statistical Analysis. 
 Statistical analysis was performed with an acceptable level 
of significance α = 0.05. The Kolmogorov-Smirnov criterion, 
which was calculated in the IBM PSPP program with a General 
public license, was used to assess the compliance of the 
distribution of the AOA values of blood serum with the normal 
distribution. Statistical processing of the measurement results was 
carried out in Microsoft Excel 2010. The results are presented as X 
± ΔX, where X is the average value, ΔX is the standard deviation. 
The statistical relationship between the parameters was estimated 
using the Pearson linear correlation coefficient, and the statistical 
significance of the differences between the parameters was 
estimated based on the Student's t-test. For the qualitative 
characteristics of the correlation relationships of the parameters, 
the Cheddok scale was used. text. 
3. RESULTS  
3.1. Evaluation of the normal distribution of AOA serum 
values. 
 The Kolmogorov-Smirnov test revealed no significant 
differences between the empirical distribution of AOA values of 
blood serum and the normal distribution: K-Sexp. = 0.05 less than 
K-Steor. = 0.08 and AS = 0.431 is more than p = 0.05 for n = 305 
(Fig. 1). 
3.2. Study of healthy volunteers. 
In the group of 110 healthy volunteers, 38.0 ± 13.2 years old, the 
average level of serum АОА was 1.22 ± 0.28 mmol-eq l–1. Table 1 
presents the results of the analysis of blood serum AOA for men 
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and women separately, and the levels of AOA in blood serum, 
which was obtained in the different time of fasting period 
duration. The data in Table 1 show that the AOA of the serum did 
not differ significantly between men and women in group of 
healthy volunteers. The average AOA value of the blood serum of 
healthy volunteers, whose blood was taken from 7.00 till 08.30 
am, is significantly (t-test) higher than the level of AOA of those 
volunteers, whose blood sample was taken later than 08.30 am 
(from 8.31 till 10.00), after the more prolonged fasting period. 
These results demonstrate the strict need to comply with the time 
of blood sampling for AOA analysis (the minimal duration of 
fasting period in morning before blood sampling). According to 
those results, volunteers whose blood sampling was performed at 
period from 07.00 till 08.30 were selected as the control group. 
 
 
Figure 1. Histogram of frequency distribution of serum AOA values of 
healthy volunteers and patients involved in the study (total n = 305). The 
solid line shows the theoretical normal distribution curve. K-S: value of 
statistics Kolmogorov-Smirnov; AS: asymptotic significance. 
 
Table 1. AOA of blood serum of healthy volunteers (n = 110). 
Subgroup АОА, mmol-eq l–1 t-test 
Men (n = 42) 
Women (n = 68) 
1.21 ± 0.26 
1.22 ± 0.30 
non-significantly 
difference 
Time of blood sampling: 
07.00–08.30 am (n = 36) 
8.31–10.00 am (n = 74) 
 
1.42 ± 0.29 





3.3. Study of patients with cardiovascular diseases. 
 In the group of 170 patients 56.5 ± 16.7 years old with 
arterial hypertension, the average level of serum АОА was 1.09 ± 
0.29 mmol-eq l–1. The results of AOA measurements in 
comparison with other tests of patients with arterial hypertension 
are presented in the Table 2, where the patients are divided into 
subgroups according to the stage of HT (by the European Society 
of Cardiology Guidelines) and presence of CAD. In general, 
differences in the AOA values of blood serum in subgroups of 
patients with different stages of HT had a non-significantly (t-test) 
character. Only the serum AOA level in subgroup of patients with 
HT 1 stage was significantly higher than the serum AOA level in 
patients of other subgroups -HT stage 2, HT stage 3 and HT stage 
3 complicated with CAD (t-test). 
3.4. Study of patients with cancer. 
 In the group of 25 patients 57.4 ± 13.7 years old with 
cancer (verified adenocarcinomas of different locations), the 
average serum АОА level was 0.70 ± 0.21 mmol-eq l–1. The 
results of AOA study patients with cancer are presented in 
Table 3, where the subgroups of patients with generalized and 
non-generalized forms of adenocarcinomas were formed. Serum 
AOA level of patients with generalized forms of cancer was 
slightly lower than this value observed in patients with non-
generalized forms, however, this difference was not statistically 
significant (t-test). 
 
Table 3. AOA of blood serum of patients with cancer (n = 25). 
Subgroup АОА, mmol-eq l–1 t-test 
Generalized forms of 
cancer (n = 10) 
Non-generalized forms of 
cancer (n = 15) 
 
0.64 ± 0.15 
 





3.5. Correlation analysis. 
 Correlation analysis for a group of healthy volunteers has 
revealed only the weak correlation between serum AOA and other 
blood counts (biochemical and full blood count tests). In group of 
patients with HT the positive moderate correlation (r = 0.48) of 
serum АОА with serum uric acid level, and negative moderate 
(r = –0.45) correlation of serum АОА with the pulse wave 
velocity in the vessels of muscle type (Sm) was established. In the 
group of patients with cancer the positive noticeable (r = 0.64) 
correlation for serum AOA with the level of uric acid was 
obtained. The results of the correlative analysis for uric acid are 
presented in Fig. 2. 
 
 
Figure 2. Pearson's correlation coefficient (r) between AOA and uric acid 
in the serum of patients with CVD (a) and patients with cancer (b). 
 
 Absolute values of AOA and uric acid concentration in 
serum for patient with CVD and cancer are shown in Fig. 3, from 
which it can be seen that these parameters are changed in different 
directions, which contradicts the results of the correlation analysis 
(Fig. 2). 
3.6. Determination of preliminary reference values of serum 
AOA. 
 Fig. 4a shows the frequencies of AOA serum values 
distribution in three groups: control, patients with and patients 
with cancer. Analysis of these distributions allows us to conclude 
that no more than 10 % of patients with CVD fall into the group 
with AOA > 1.40 mmol-eq l–1, and no more than 10 % of patients 
with cancer fall into the group with AOA > 0.95 mmol-eq l–1. 
Based on this, we have identified three ranges of AOA for the 
purpose of assessing the state between healthy and ill patients 
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(Fig. 4b). Three areas of AOA values are presented for groups: (i) 
of healthy people (AOA ≥ 1.40 mmol-eq l–1), (ii) patients who are 
at risk (AOA from 0.95 to 1.40 mmol-eq l–1) and (iii) seriously ill 
patients (AOA < 0.95 mmol-eq l–1). In the last second and 
particularly in the third groups detailed diagnostics 
and relevant treatment are required. 
 
Figure 3. The values of the AOA and the concentration of uric acid in the 
serum of 170 patients with CVD (a) and 25 patients with cancer (b). 
 
 
Figure 4. The frequency distribution of serum AOA values in control 
group (n = 36), group of patients with CVD (n = 170) and group of 
patients with cancer (n = 25) (a); diagram of serum AOA values for 
assessing the state "healthy – ill" people (b).
Table 2. The results of serum AOA, biochemical tests, full blood count test, pulse wave velocity and IMT in patients with arterial hypertension 
(n = 170). 
Parameter HT stage 1 
(n = 49) 
HT stage 2 
(n = 63) 
HT stage 3 
(n = 24) 
HT stage 3 complicated 
with CAD (n = 34) 
АОА, mmol-eq l–1 1.12 ± 0.23 1.01 ± 0.29 1.07 ± 0.33 1.25 ± 0.31 
Glucose, mmol l–1 5.5 ± 2.0 5.7 ± 1.8 5.9 ± 1.2 5.4 ± 0.7 
HGB, g l–1 148.5 ± 13.7 146.1 ± 14.3 140.2 ± 19.3 144.0 ± 13.7 
Total cholesterol, mmol l–1 4.8 ± 1.1 5.7 ± 1.3 5.4 ± 1.4 5.2 ± 1.4 
LDL, mmol l–1 2.6 ± 1.4 3.5 ± 1.0 3.8 ± 1.3 3.5 ± 1.5 
HDL, mmol l–1 1.1 ± 0.4 1.5 ± 0.6 1.7 ± 0.8 1.1 ± 0.3 
WBC count, 109 l–1 5.5 ± 1.3 6.8 ± 2.1 7.2 ± 1.6 7.3 ± 2.1 
RBC count, 1012 l–1 4.7 ± 0.5 4.9 ± 0.5 4.8 ± 0.5 4.8 ± 0.4 
HCT, % 42.7 ± 2.3 42.4 ± 3.9 41.5 ± 4.0 42.1 ± 3.7 
Uric acid, μmol l–1 343.5 ± 103.8 319.8 ± 108.1 353.8 ± 193.7 378.7 ± 99.0 
Creatinine, μmol l–1 90.3 ± 18.0 86.0 ± 15.0 91.7 ± 12.9 96.2 ± 26.2 
Sm, m s–1 10.3 ± 8.8 16.5 ± 12.8 21.8 ± 10.8 11.7 ± 4.5 
Se, m s–1 13.2 ± 7.8 11.4 ± 7.2 20.9 ± 6.7 18.1 ± 12.1 
Sm/Se 0.8 ± 0.5 1.9 ± 1.7 1.0 ± 0.3 0.7 ± 0.2 
IMT L, mm 0.07 ± 0.02 0.07 ± 0.02 0.09 ± 0.02 0.11 ± 0.02 
IMT R, mm 0.07 ± 0.02 0.07 ± 0.02 0.09 ± 0.02 0.10 ± 0.02 
AOA: antioxidant activity; CAD: coronary artery disease (ischemic heart disease); CVD: cardiovascular diseases; HCT: hematocrit (packed cell volume); HDL: 
high density lipoproteins; HGB: hemoglobin; HT: arterial hypertension; IMT: intima-media thickness; IMT L and IMT R: intima-media thickness of left (L) 
and right (R) common carotid artery; LDL: low density lipoproteins; RBC: red blood cells count; Se: pulse wave velocity through the vessels of elastic type; 
Sm: pulse wave velocity through the vessels of muscle type; WBC: white blood cells count. 
4. DISCUSION 
 The dependence of the AOA value of the healthy 
volunteers on the time of blood collection, of course, has 
fundamental importance for the correct determination of the 
normal values of this indicator, and for the better understanding of 
the mechanisms, changing the level of AOA. In our opinion, the 
lower AOA rates in volunteers whose blood was taken for analysis 
at a later time can be explained from the standpoint of the stress 
theory of Hans Selye. The stress factor in this case is short nutrient 
deprivation. It is known that the enhance in the intensity of redox 
reactions occurs when the body's demand in energy is increased, 
and the body reacts by the generating of energy during the 
excitation phase of the stress. In aerobic organisms, it is the energy 
of redox reactions. The generation of energy is accompanied by 
the formation of more ROS, which is normally compensated by 
the elevated antioxidants synthesis and/оr its supplement with 
food. In conditions of starvation, their reserves become depleted 
and OS appears. This is confirmed by the data of V. Luschak [32], 
who demonstrated the parabolic nature of changes in antioxidants 
concentrations in dynamics at different stress phases. The big 
problem is to understand, what phase of stress we measure in 
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plasma, what part of oxidants appear here from the cells after 
intracellular OS, what happens at the border between cell and 
extracellular environment, and what is the dependence between 
AOA of plasma and quantity and properties of oxidants, synthesed 
in cell and left out of its biomembrane? This requires in-depth 
research and cannot be performed as part of this work. 
Thus, the correct AOA levels can be obtained under the 
compliance of the correct time period for blood collection – in the 
early morning after waking up. Coming within a few hours of 
fasting first phase of stress (excitation phase) leads to an increase 
in the severity of OS and understated levels of AOA, probably due 
to depletion of stocks of antioxidants. 
 Certainly, more researches are needed on healthy patients 
with the modeling of dependence of AOA on the duration of the 
fasting period, the comparison of these data with the subsequent 
reaction of AOA for a meal. 
 The decrease in AOA levels in patients with cardiovascular 
pathology compared to the control group is a reflection of the OS, 
which plays an important role in CVD pathogenesis. 
In many modern works, OS is considered as an important 
"pathogenetic link" in the pathology of the cardiovascular system 
in connection with the strengthening under its influence of nitric 
oxide (NO) and vascular endothelial disorders, which plays a key 
role in many diseases of the cardiovascular system, including 
atherosclerosis (atherogenesis), hypertension, coronary artery 
disease, thrombosis, heart failure and stroke [33–35]. 
 In physiological conditions, the ROS does not have a 
significant impact on the production of nitric oxide [36]. In the 
presence of cardiovascular risk factors, the production of 
superoxide and other ROS leads to rapid inactivation of the nitric 
oxide, and its effects decrease, and the formation of high 
concentrations of the potent pro-oxidant peroxynitrite, which has a 
toxic effect on the endothelial cells [37] and leads to its 
dysfunction. OS is deeply involved in the pathogenesis of 
hypertension. These effects are mediated by the inactivation of 
nitric oxide by ROS in the vasculature and kidney, as well as 
H2O2–induced vascular remodeling [38]. 
In the study [39], a direct correlation between the average blood 
pressure and the concentration of products of reactions with 
thiobarbituric acid (TBARS), an important marker of oxidative 
degradation of lipids was demonstrated. It is noted that OS plays a 
key role in the different processes and mechanisms related to 
arterial hypertension, such as vascular remodeling, inflammation, 
endothelial dysfunction, the development of atherosclerotic 
plaques, the formation of aortic aneurysms, as well as 
vasoconstriction, endocrine dysregulation, and the activity of 
nervous and emotional factors that stimulate hypertension [40–
44]. 
 In our opinion, the decrease in the value of AOA in patients 
with hypertension reflects the presence of OS, damaging primarily 
the system of vascular regulation- the central link in the 
pathogenesis of hypertension, which is confirmed by our data on 
the existence of an inverse correlation between the value of AOA 
and the pulse wave velocity through the vessels of muscle type, 
i.e., showing the relationship of reducing the level of AOA with 
increasing stiffness of the vascular wall. It is important to know 
that such correlation was not obtained with the thickness of the 
intima-media complex of carotid arteries, as well as with the levels 
of total cholesterol and high-and low-density lipoproteins. It 
indicates, rather, that structural changes in vascular smooth 
muscles possibly have the greater influence on the level of AOA 
and on the severity of OS than concomitant lipid metabolism 
disorders. Probably it reflects the damaging effect of OS out of 
cell, in extracellular space, during the processes of vascular 
remodeling. This hypothesis, of course, needs to be tested and is 
likely to determine the key mechanisms of the impact of the OS on 
the cardiovascular system, its possible differences and regularities 
of their development in hypertension and atherosclerosis. 
 Uric acid is the final product of purine metabolism and 
holds a special place among water-soluble antioxidants [45] since 
it accounts for 35 to 65 % of the activity of antioxidant protection 
of lipoproteins from free radical oxidation. The antioxidant 
properties of uric acid are related to its ability to inactivate strong 
(strong transient) oxidants by means of an electron subsidy. This 
property is usually enhanced by the protonated state of the 
molecule of uric acid and the intermediate state of the free radical 
[46]. The antioxidant action of the uric acid is chelation of iron 
and copper ions that initiate free radical processes; it interacts with 
the free radicals (О2
•–, OH•), and peroxynitrite (ONOO–); enhances 
the antioxidant effects of α-tocopherol and ascorbic acid, etc. 
 With the development of pathological conditions, the 
content of uric acid as a result of the response of the body 
increases significantly, and begin to show its pro-oxidant 
properties. In the Framingham study noted that elevated serum 
uric acid levels were associated with an increased risk of coronary 
heart disease and accelerated atherosclerosis in men aged 30–59 
years [47]. Uric acid is able to stimulate the proliferation of 
smooth muscle cells of blood vessels, reduces the production of 
nitric oxide in endothelial cells. The question of correlation of 
concentration of uric acid with the total AOA of blood plasma is 
insufficiently studied, there is a contradiction between the 
expressed antioxidant properties of uric acid, and increase in the 
risk of development of CVD at its high concentration [48, 49]. 
Increasing the concentration of uric acid is considered as an 
adaptive response to the increasing OS in heart failure, which 
allows preserving the endothelial function through increasing the 
activity of extracellular superoxide dismutase [45]. In general, the 
AOA index did not show a direct dependence on the uric acid 
content, which can be a consequence of its pro-oxidant properties.  
 This confirms our postulate about the need for an integrated 
assessment of the OS. 
 A very important finding, which possibly can be considered 
as the diagnostic tool (the future studies are needed), is a 
significant reduction of AOA of blood serum of patients with 
malignant neoplasms in compare to the control group. 
 The malignant neoplasms growth in humans is associated 
with complex processes at the cellular and molecular levels, which 
are caused by various endogenous and exogenous causes, and the 
OS mechanisms play an obvious role in their implementation. 
Thus, ROS can induce mutagenesis, which can cause malignant 
transformation of the cells, using a variety of possible mechanisms 
(breaking of DNA chains, formation of DNA-adducts, activation 
of oncogenes, inactivation of tumor suppressor genes, DNA 
modification, etc.). Interaction of ROS with tumor suppressor 
genes and proto-oncogenes indicates their role in the occurrence of 
different types of human cancer. OS can stimulate carcinogenesis 
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also through epigenetic mechanisms that affect proliferation cell 
differentiation and apoptosis, oxidant changes in protein structure 
and functions, that, in particular can lead to transform normal cells 
into malignant [50–52]. Some ROS (for example, malonic 
dialdehyde), have a high cytotoxic and inhibitory action on 
protective enzymes, also act as the tumor promoters or co-
carcinogenes, which was shown in some types of malignant 
tumors (breast cancer) [53]. Despite the large number of works, 
studying OS and antioxidants role in cancer, at the present time it 
does not allow to come to general conclusions about their role in 
cancer growth. Despite the malignant tumors metabolism has 
common patterns; the assertion that the sharp decrease in AOA 
can be a possible sign of tumor growth must be approached very 
carefully despite the first promising results of this study. The 
special well-designed clinical trials are needed to support this 
hypothesis. 
 Special research is needed for understanding the 
mechanism of those processes and their role in pathogenesis of 
neoplasms. 
5. CONCLUSIONS, PROBLEMS, TRENDS 
 It is an accepted idea this time, that OS is an essential part 
of pathological processes in a living organism. The measure of its 
manifestation is the reducing of the AOA of biological fluids and 
tissues. As the origin and effect of OS are determined by the ox-
red chemical reactions, the use of such kind of the reaction as 
signal generating one is important in the used analysis method. 
That is why HPM that includes correctly chosen mediator system 
is preferable to be used in laboratory clinic analysis for AOA 
determination.  
 The paper presents the results of own measurements of 
AOA of blood serum in healthy volunteers and patients with 
various diseases. The lower levels of AOA of blood serum in 
patients with CVD and malignancy in compare with the healthy 
volunteers are observed. Preliminary reference values of AOA 
blood serum are established. Thus, three areas of AOA values are 
observed in the groups: 
 healthy people, AOA ≥ 1.40 mmol-eq l–1; 
 who are at risk,   0.95 mmol-eq l–1 ≤ AOA < 1.40 mmol-eq l–
1; 
 ill people, AOA < 0.95 mmol-eq l–1. 
 In the process of research, a very interesting fact was noted: 
the decrease in the AOA during fasting, which indicates the 
appearance of the OS and the need to observe a temporary regime 
during the analysis. These findings can be used in mass screening 
in medicine. 
 It is extremely important, that low AOA can be considered 
as a potential "red flag" because it was obtained in patients with 
malignant tumors – the detection of low AOA values in patients 
during screening can provide the physician with additional 
information suggesting a diagnostic search for malignancy. 
 The findings allow suggesting that the determination of 
AOA of biological fluids holds considerable promise for 
monitoring OS of the whole organism and its systems, it opens up 
new opportunities in expanding the use of clinical laboratory 
analysis in the evaluation of health state.  
 Most biochemical reactions in a living organism are 
heterogeneous, occurring on biointerfaces whose total surface is 
enormous. Whereas the implementation of the biochemical chain 
of ROS formation begins and mostly occurs in mitochondria as a 
heterogeneous process, and the reactions of ROS and RNS with 
antioxidants are hetero - or homogeneous depending on the nature 
of the antioxidants (hydro - or lipophilic) and place of their course. 
Taking into account the last circumstance, as well as: 
 common redox interactions-reactions of oxidants with 
antioxidants, 
 the relationship of these reactions with OS and the latter with 
AOA, 
 a significant role of OS in pathologies, 
 sufficient ease of monitoring OS by the magnitude of AOA, 
it can be assumed that an in-depth and comprehensive study of 
AОA patients with various diseases will provide at least indirect 
information about the role of biointerface in the pathogenesis of 
various diseases. 
 Despite the apparent clarity of the above representations, it 
is necessary to point out the complexity and multifactorial nature 
of the above reactions. On closer examination, it is necessary to 
consider how pronounced is OS within cells, and how many 
products and what kind of them are released into the bloodstream 
(extracellular space) and activate the security system. This 
depends on the state and functioning of the barrier biological 
membranes, and the response of the antioxidant defense system to 
the release of oxidants, and the patterns of damage to the 
biomembranes, ie. from a complex of interactions of oxidants and 
antioxidants in different environments and at the interface of these 
environments, the resulting integral indicator is the AOA of 
biological environments (blood plasma, seminal fluid, saliva, skin, 
etc.) The clear understanding of processes of interaction of 
oxidants, leading to the emergence of OS, and antioxidants, 
determining the activity of the antioxidant defense system, in cells, 
intercellular environment and membranes and at the interface 
require serious research. The development of OS and AOA 
monitoring methods can help to optimize the treatment process of 
some diseases, for example, to find the right time and place of 
administration of antioxidants in cancer. 
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